Keywords: 4 years; interleukin 17; ixekizumab; long-term; open-label; psoriasis; BCC; basal cell carcinoma; DLQI; Dermatology Life Quality Index; HADS; Hospital Anxiety and Depression Scale; IBD; inflammatory bowel disease; IL; interleukin; LOCF; last observation c
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: enthesitis; nail; onycholysis; psoriatic arthritis; splinter hemorrhage; transverse grooves; CI; confidence interval; DIP; distal interphalangeal; NAPSI; Nail Psoriasis Severity Index; OR; odds ratio; PASI; Psoriasis Area and Severity Index; PsA; psoriati
Keywords: assessment tool; nail psoriasis; Nail Psoriasis Severity Index; Nijmegen-Nail Psoriasis Activity Index Tool; psoriasis; scoring systems; ICC; intraclass correlation coefficient; NAPSI; Nail Psoriasis Severity Index; N-NAIL; Nijmegen-Nail psoriasis Act
Keywords: Beau lines; epidemiology; leukonychia; nail psoriasis; Nail Psoriasis Severity Index; nails; onycholysis; psoriasis; splinter hemorrhages; NAPSI; Nail Psoriasis Severity Index; PASI; Psoriasis Area and Severity Index; PsA; psoriatic arthritis;
Adalimumab for nail psoriasis: Efficacy and safety from the first 26Â weeks of a phase 3, randomized, placebo-controlled trial
Keywords: adalimumab; mNAPSI; nail pain; nail psoriasis; NAPSI; NPPFS; phase 3 placebo-control; skin psoriasis; B-SNIPI50 (scalp); 50% or more improvement in the scalp portion of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index; BSA; body surface area;
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108Â weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Keywords: efficacy; interleukin 17; ixekizumab; long-term; psoriasis; safety; UNCOVER-3; AE; adverse event; CI; confidence interval; IL; interleukin; LTE; long-term extension; MI; multiple imputation; mMI; modified multiple imputation; NAPSI; Nail Psoriasis Severit
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-
Keywords: adalimumab; efficacy; guselkumab; hand and foot psoriasis; nail psoriasis; psoriasis; safety; scalp psoriasis; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; f-PGA; Fingernail Physician Global Assessment; HRQoL; health-relate
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)
Keywords: apremilast; nail psoriasis; phosphodiesterase 4 inhibitor; psoriasis; scalp psoriasis; systemic therapy; BID; twice daily; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; NAPSI; Nail Psoriasis Severity Index; NAPSI-50;